Full Press Release Details
Northstrive Biosciences Signs Partnership with Yuva Biosciences
to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases
NEWPORT BEACH, Calif., Apr. 10, 2025 (GLOBE NEWSWIRE) -- Northstrive
Biosciences Inc. ("Northstrive" or "Northstrive Biosciences"), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB)
("PMGC," "we," or "our"), announced today that it has entered into a Development and License Agreement
("Agreement") with Yuva Biosciences, Inc. ("YuvaBio" or "Yuva Biosciences") to discover and develop
novel pharmaceutical treatments for obesity, type 2 diabetes and other cardiometabolic conditions using YuvaBio's proprietary, mitochondrial
science-focused platform MitoNova, powered by artificial intelligence ("AI").
The Agreement provides for the parties' collaboration on an AI
Development Program ("Program" or "AI Development Program"). As part of this Program, YuvaBio will develop mitochondrial
science related technology for Northstrive and identify drug candidates with the potential to improve mitochondrial health and cardiometabolic
function. YuvaBio will then test its computational findings for biological activity on custom assays. YuvaBio will also grant Northstrive
an exclusive, worldwide license to this developed technology to derive therapeutic products for cardiac diseases and obesity. Through
this collaboration, the parties aim to integrate new methodologies into mitochondrial biology and discover outputs to expand Northstrive's
cardiometabolic disease pipeline.
The AI Development Program will combine YuvaBio's proprietary
AI platform with laboratory validation to identify and advance novel drug candidates targeting mitochondrial function. The multi-phase
collaboration includes in silico modeling, virtual compound screening, and experimental testing to shortlist promising candidates for
clinical development.
"Declining mitochondrial function not only accelerates aging
but also plays a central role in numerous age-related disorders and other pathologies such as obesity," said Greg Schmergel, Co-Founder
and CEO of Yuva Biosciences. "With this collaboration, we will be leveraging our proprietary AI to discover compounds that are mitochondrial
promoters and protectors and verify the findings with experimental wet lab testing."
YuvaBio's MitoNova provides an integrated suite of AI-enabled
tools that analyze vast datasets and explore compound libraries across multiple dimensions of chemical and bioactivity properties. Leveraging
a proprietary mitochondrial database and leading-edge AI models, MitoNova identifies compounds that target the root cause of aging and
related conditions at the cellular level. Research teams can then utilize MitoNova to assess key factors such as bioavailability and safety
to accelerate the transition from target discovery to biological validation.
"We are believers in leveraging AI to guide our drug development
efforts and view mitochondrial health as a foundational pillar," said Deniel Mero, Co-Founder of Northstrive Biosciences. "YuvaBio
is the ideal partner for this collaboration, and we expect it to lead to the identification of several novel targets that may form the
basis of differentiated cardiometabolic drug programs."
In exchange for the rights and license granted to Northstrive under
the Agreement, Yuva will receive: (i) an upfront fee upon the parties' entry into the Agreement and payments made based on initiation
and completion of phases in the Program, (ii) certain developmental milestone payments, and (iii) royalties on net sales of certain therapeutic
cardiac disease and obesity products from Northstrive (or its affiliates, or sublicensees) which contain the final shortlist of promising
compounds that YuvaBio identifies and recommends as a result of the Program.
About Northstrive Biosciences Inc.
Northstrive Biosciences Inc., a PMGC Holdings Inc. company, is a biopharmaceutical
company focusing on the development and acquisition of cutting-edge aesthetic medicines. Northstrive Biosciences' lead asset,
EL-22, leverages an engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss
treatments, including GLP-1 receptor agonists. For more information, please visit www.northstrivebio.com.
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company that manages and
grows its portfolio through strategic acquisitions, investments, and development across various industries. Currently, our portfolio consists
of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. We are committed to exploring
opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.
About Yuva Biosciences, Inc.
Yuva Biosciences is a longevity company harnessing the cutting edge
of mitochondrial science to address the root cause of aging. By partnering with consumer brands and biotech innovators, Yuva Biosciences
develops solutions for aging-related concerns including hair loss, skin wrinkles, and several other conditions driven by a decline in
mitochondrial function. The company is headquartered in Birmingham, Alabama. For more information, please visit www.yuvabio.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of
1995, as amended. Words such as "believes," "expects," "plans," "potential," "would"
and "future" or similar expressions such as "look forward" are intended to identify forward-looking statements.
Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance.
Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and
strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future
conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations
expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct,
and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely
on any of these forward-looking statements. These and other risks are described more fully in PMGC Holdings' filings with the United
States Securities and Exchange Commission ("SEC"), including the "Risk Factors" section of the Company's
Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025, and its other documents subsequently
filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's
web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were
made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were made.